The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Osteoarthritis Pain Market Research Report 2025
Synopsis
Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.
The global Drugs for Osteoarthritis Pain market was valued at US$ 9238.5 million in 2023 and is anticipated to reach US$ 13870 million by 2030, witnessing a CAGR of 5.9% during the forecast period 2024-2030.
North America is the largest Drugs for Osteoarthritis Pain market with about 36% market share. Europe is follower, accounting for about 27% market share.
The key players are Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma etc. Top 5 companies occupied about 66% market share.
This report aims to provide a comprehensive presentation of the global market for Drugs for Osteoarthritis Pain, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Osteoarthritis Pain.
Report Scope
The Drugs for Osteoarthritis Pain market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Osteoarthritis Pain market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Osteoarthritis Pain companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Johnson & Johnson
GlaxoSmithKline
Bayer
Eli Lilly
Novartis
Sanofi
Horizon Pharma
Abbott
Mylan
Daiichi Sankyo
TEVA
Almatica Pharma
Astellas Pharma
Tide Pharmaceutical
Iroko Pharmaceuticals
Hengrui Pharmaceutical
Abiogen Pharma
Segment by Type
Oral
Injection
External
Segment by Application
Medical Care
Personal Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Osteoarthritis Pain companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.
The global Drugs for Osteoarthritis Pain market was valued at US$ 9238.5 million in 2023 and is anticipated to reach US$ 13870 million by 2030, witnessing a CAGR of 5.9% during the forecast period 2024-2030.
North America is the largest Drugs for Osteoarthritis Pain market with about 36% market share. Europe is follower, accounting for about 27% market share.
The key players are Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma etc. Top 5 companies occupied about 66% market share.
This report aims to provide a comprehensive presentation of the global market for Drugs for Osteoarthritis Pain, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Osteoarthritis Pain.
Report Scope
The Drugs for Osteoarthritis Pain market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Osteoarthritis Pain market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Osteoarthritis Pain companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Johnson & Johnson
GlaxoSmithKline
Bayer
Eli Lilly
Novartis
Sanofi
Horizon Pharma
Abbott
Mylan
Daiichi Sankyo
TEVA
Almatica Pharma
Astellas Pharma
Tide Pharmaceutical
Iroko Pharmaceuticals
Hengrui Pharmaceutical
Abiogen Pharma
Segment by Type
Oral
Injection
External
Segment by Application
Medical Care
Personal Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Osteoarthritis Pain companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Osteoarthritis Pain Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Injection
1.2.4 External
1.3 Market by Application
1.3.1 Global Drugs for Osteoarthritis Pain Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Medical Care
1.3.3 Personal Care
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Osteoarthritis Pain Market Perspective (2019-2030)
2.2 Drugs for Osteoarthritis Pain Growth Trends by Region
2.2.1 Global Drugs for Osteoarthritis Pain Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs for Osteoarthritis Pain Historic Market Size by Region (2019-2024)
2.2.3 Drugs for Osteoarthritis Pain Forecasted Market Size by Region (2025-2030)
2.3 Drugs for Osteoarthritis Pain Market Dynamics
2.3.1 Drugs for Osteoarthritis Pain Industry Trends
2.3.2 Drugs for Osteoarthritis Pain Market Drivers
2.3.3 Drugs for Osteoarthritis Pain Market Challenges
2.3.4 Drugs for Osteoarthritis Pain Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Osteoarthritis Pain Players by Revenue
3.1.1 Global Top Drugs for Osteoarthritis Pain Players by Revenue (2019-2024)
3.1.2 Global Drugs for Osteoarthritis Pain Revenue Market Share by Players (2019-2024)
3.2 Global Drugs for Osteoarthritis Pain Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Osteoarthritis Pain Revenue
3.4 Global Drugs for Osteoarthritis Pain Market Concentration Ratio
3.4.1 Global Drugs for Osteoarthritis Pain Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Osteoarthritis Pain Revenue in 2023
3.5 Drugs for Osteoarthritis Pain Key Players Head office and Area Served
3.6 Key Players Drugs for Osteoarthritis Pain Product Solution and Service
3.7 Date of Enter into Drugs for Osteoarthritis Pain Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Osteoarthritis Pain Breakdown Data by Type
4.1 Global Drugs for Osteoarthritis Pain Historic Market Size by Type (2019-2024)
4.2 Global Drugs for Osteoarthritis Pain Forecasted Market Size by Type (2025-2030)
5 Drugs for Osteoarthritis Pain Breakdown Data by Application
5.1 Global Drugs for Osteoarthritis Pain Historic Market Size by Application (2019-2024)
5.2 Global Drugs for Osteoarthritis Pain Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs for Osteoarthritis Pain Market Size (2019-2030)
6.2 North America Drugs for Osteoarthritis Pain Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs for Osteoarthritis Pain Market Size by Country (2019-2024)
6.4 North America Drugs for Osteoarthritis Pain Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Osteoarthritis Pain Market Size (2019-2030)
7.2 Europe Drugs for Osteoarthritis Pain Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs for Osteoarthritis Pain Market Size by Country (2019-2024)
7.4 Europe Drugs for Osteoarthritis Pain Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Osteoarthritis Pain Market Size (2019-2030)
8.2 Asia-Pacific Drugs for Osteoarthritis Pain Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs for Osteoarthritis Pain Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs for Osteoarthritis Pain Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Osteoarthritis Pain Market Size (2019-2030)
9.2 Latin America Drugs for Osteoarthritis Pain Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs for Osteoarthritis Pain Market Size by Country (2019-2024)
9.4 Latin America Drugs for Osteoarthritis Pain Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Osteoarthritis Pain Market Size (2019-2030)
10.2 Middle East & Africa Drugs for Osteoarthritis Pain Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs for Osteoarthritis Pain Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs for Osteoarthritis Pain Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Drugs for Osteoarthritis Pain Introduction
11.1.4 Pfizer Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Drugs for Osteoarthritis Pain Introduction
11.2.4 Johnson & Johnson Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Drugs for Osteoarthritis Pain Introduction
11.3.4 GlaxoSmithKline Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Drugs for Osteoarthritis Pain Introduction
11.4.4 Bayer Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Detail
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Drugs for Osteoarthritis Pain Introduction
11.5.4 Eli Lilly Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.5.5 Eli Lilly Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Drugs for Osteoarthritis Pain Introduction
11.6.4 Novartis Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Drugs for Osteoarthritis Pain Introduction
11.7.4 Sanofi Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.7.5 Sanofi Recent Development
11.8 Horizon Pharma
11.8.1 Horizon Pharma Company Detail
11.8.2 Horizon Pharma Business Overview
11.8.3 Horizon Pharma Drugs for Osteoarthritis Pain Introduction
11.8.4 Horizon Pharma Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.8.5 Horizon Pharma Recent Development
11.9 Abbott
11.9.1 Abbott Company Detail
11.9.2 Abbott Business Overview
11.9.3 Abbott Drugs for Osteoarthritis Pain Introduction
11.9.4 Abbott Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.9.5 Abbott Recent Development
11.10 Mylan
11.10.1 Mylan Company Detail
11.10.2 Mylan Business Overview
11.10.3 Mylan Drugs for Osteoarthritis Pain Introduction
11.10.4 Mylan Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.10.5 Mylan Recent Development
11.11 Daiichi Sankyo
11.11.1 Daiichi Sankyo Company Detail
11.11.2 Daiichi Sankyo Business Overview
11.11.3 Daiichi Sankyo Drugs for Osteoarthritis Pain Introduction
11.11.4 Daiichi Sankyo Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.11.5 Daiichi Sankyo Recent Development
11.12 TEVA
11.12.1 TEVA Company Detail
11.12.2 TEVA Business Overview
11.12.3 TEVA Drugs for Osteoarthritis Pain Introduction
11.12.4 TEVA Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.12.5 TEVA Recent Development
11.13 Almatica Pharma
11.13.1 Almatica Pharma Company Detail
11.13.2 Almatica Pharma Business Overview
11.13.3 Almatica Pharma Drugs for Osteoarthritis Pain Introduction
11.13.4 Almatica Pharma Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.13.5 Almatica Pharma Recent Development
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Detail
11.14.2 Astellas Pharma Business Overview
11.14.3 Astellas Pharma Drugs for Osteoarthritis Pain Introduction
11.14.4 Astellas Pharma Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.14.5 Astellas Pharma Recent Development
11.15 Tide Pharmaceutical
11.15.1 Tide Pharmaceutical Company Detail
11.15.2 Tide Pharmaceutical Business Overview
11.15.3 Tide Pharmaceutical Drugs for Osteoarthritis Pain Introduction
11.15.4 Tide Pharmaceutical Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.15.5 Tide Pharmaceutical Recent Development
11.16 Iroko Pharmaceuticals
11.16.1 Iroko Pharmaceuticals Company Detail
11.16.2 Iroko Pharmaceuticals Business Overview
11.16.3 Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Introduction
11.16.4 Iroko Pharmaceuticals Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.16.5 Iroko Pharmaceuticals Recent Development
11.17 Hengrui Pharmaceutical
11.17.1 Hengrui Pharmaceutical Company Detail
11.17.2 Hengrui Pharmaceutical Business Overview
11.17.3 Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Introduction
11.17.4 Hengrui Pharmaceutical Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.17.5 Hengrui Pharmaceutical Recent Development
11.18 Abiogen Pharma
11.18.1 Abiogen Pharma Company Detail
11.18.2 Abiogen Pharma Business Overview
11.18.3 Abiogen Pharma Drugs for Osteoarthritis Pain Introduction
11.18.4 Abiogen Pharma Revenue in Drugs for Osteoarthritis Pain Business (2019-2024)
11.18.5 Abiogen Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
